LeMaitre Vascular (LMAT) director gains shares via dividend rights

Rhea-AI Filing Summary

LeMaitre Vascular reported a director receiving additional common shares through equity awards. On 12/12/2025, the director acquired 5 shares of common stock in each of two transactions at a stated price of $0 per share, reflecting the release of dividend equivalent rights tied to earlier stock awards. After these transactions, reported beneficial ownership entries were 5,317 and 5,322 common shares held directly. Related dividend equivalent right positions were reduced to zero, with any fractional shares settled in cash at vesting.

Insider Trade Summary

10 shares exercised/converted

Mixed 4 txns

Insider Jasinski Lawrence J

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	5	$0.00	--
Exercise	Dividend Equivalent Rights	5	$0.00	--
Exercise	Common Stock	5	$0.00	--
Exercise	Common Stock	5	$0.00	--

Holdings After Transaction: Dividend Equivalent Rights — 0 shares (Direct); Common Stock — 5,317 shares (Direct)

Footnotes (1)

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jasinski Lawrence J

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		5(1)	A	$0(1)	5,317	D
Common Stock	12/12/2025		M		5(1)	A	$0(1)	5,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(2)	12/12/2025		M			5(2)	(2)	(2)	Common Stock	5	$0	0(3)	D
Dividend Equivalent Rights	(4)	12/12/2025		M			5(4)	(4)	(4)	Common Stock	5	$0	0(3)	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. Fractional shares (if any) were settled in cash on each vesting date, resulting in a final balance of zero.

4. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LeMaitre Vascular (LMAT) disclose in this Form 4?

A LeMaitre Vascular director reported acquiring common stock on 12/12/2025. Two transactions each added 5 shares of common stock at a stated price of $0 per share when dividend equivalent rights were released.

How many LeMaitre Vascular shares does the director beneficially own after these transactions?

Following the reported transactions, beneficial ownership entries show 5,317 and 5,322 shares of LeMaitre Vascular common stock held directly.

What are dividend equivalent rights in this LeMaitre Vascular (LMAT) Form 4?

The filing describes dividend equivalent rights where each right is the economic equivalent of one share of LeMaitre Vascular common stock and was released in connection with vesting of restricted stock unit and performance stock unit awards granted on 12/12/2022.

Were any dividend equivalent rights remaining after the reported LeMaitre Vascular transactions?

No dividend equivalent rights remained. Table II shows the number of derivative securities beneficially owned after the transactions as 0, with fractional shares, if any, settled in cash.

Did the LeMaitre Vascular director pay cash for the newly acquired shares?

The price column for the common stock acquisitions shows $0, and the explanation notes the shares were acquired upon release of dividend equivalent rights, with only any fractional shares settled in cash.

Which prior equity awards led to the LeMaitre Vascular dividend equivalent right releases?

The dividend equivalent rights were released in connection with the vesting of a restricted stock unit award and a performance stock unit award, each granted on 12/12/2022.